Loading viewer...
investor_presentation
Format: PDF investor_presentation
mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases Operational Highlights & Financial Results for the Year Ended June 30, 2022 August 2022 ASX: MSB; Nasdaq: MESO
presentation
Lateral Flow Company Investor Presentation January 2024
investor_presentation
9 Pages
Lateral Flow Company
investor_presentation
Colfax